Jump to content

Laurence Zitvogel

From Wikipedia, the free encyclopedia

Laurence Zitvogel
Born (1963-12-25) 25 December 1963 (age 60)
Sureness, France
NationalityFrench
Alma materParis University
Occupation(s)Oncologist, immunologist, researcher
HonoursBaillet Latour Awarded by the Belgian Monarchy

Laurence Zitvogel (born 25 December 1963) is a French physician-scientist specializing in oncology and immunology. Zitvogel is a clinical oncologist, a researcher in the Laboratory of Tumor Immunology and Immunotherapy, and a professor at Paris-Saclay University.[1] She has studied the correlation between the immune system and the success of cancer treatments for over 30 years.[2] Her primary research experience lies in exosomes,[3] studying the biological impact of structural abnormalities on malignant neoplasms,[4] and anti-tumor therapy.[5] Through her work as a professor and researcher, Zitvogel discovered that chemotherapy could delay the growth of tumors in mouse models.[6] Her team reported the first anticancer probiotic, Enterococcus hirae.[7] As of 2020, she is researching an effective and inexpensive diagnostic test to predict dysbiosis and is investigating the promising lead on the role of gut microbiotes in anti-tumour immunotherapy.[1]

Throughout her career, she has received numerous honors and awards ranging from the Bob Pinedo Cancer Care Award to the ESMO Award for Immuno-Oncology.

Personal life

[edit]

Laurence Zitvogel was born in Suresnes, France.[8] Zitvogel has worked with her spouse, Guido Kroemer,[9] since 2001.[10]

Education

[edit]

Zitvogel earned her degree in medical oncology from the University of Paris in 1992. Zitvogel started her scientific career in 1993 at the University of Pittsburgh (USA) in Michael Lotze's laboratory.[11][12] She received her Ph.D in Immunology at the University of Pittsburgh Cancer Institute and the Gustav Roussy Cancer Center in 1995.[13]

Career and leadership

[edit]

Zitvogel supervised work in 2013 that analyzed the multifaceted modes of action of the anticancer probiotic, Enterococcus hirae.[7] Zitvogel leads the French RHU Torino-Lumière and European Oncobiome consortia for the development of tests for gut dysbiosis associated with frequent cancers.[1] She has authored over 350 publications[14] and is the editor-in-chief and founder of one of the first journals in immune-oncology, OncoImmunology.[15]

She is a professor of immunobiology at the University of Paris XI Medical School and is a scientific director at the Department of Immuno-Oncology at the Gustave Roussy Cancer Center in Villejuif, France.[16] She is also the director of U1015 Inserm Tumour Immunology and Immunotherapy Laboratory and co-director of the Center for Clinical Investigation in Biotherapies of Cancer at Inserm.[15] Zitvogel co-founded EverImmune, a clinical-stage biotechnology company developing live biotherapeutic products as adjuncts to cancer immunotherapy.[17] Zitvogel's research team found that bacteria in the gut had a major effect on the efficacy of checkpoint inhibitors in mice.[18][6]

Research

[edit]

Zitvogel's work focuses on intestinal bacterial flora.[19][20][21] Her primary research objectives are to identify cell adhesion molecules that serve as actionable checkpoints for tumor surveillance.[4] The research group she directs has been focused on the discovery and validation of antibody combination therapies.[22]

Zitvogel discovered that cancer therapies with long-term beneficial effects may have limited impact on local disease, but should activate a relevant adaptive immune reaction.[23] Pioneering work by Zitvogel and Kroemer revealed that chemotherapy could slow the growth of tumors growing on immunocompetent mice, but had no effect on tumors established on immunodeficient mice.[23] Zitvogel set up a patient diagnosis platform that allows the patient's tumor to be removed when performing the operation.[1] Zitvogel hypothesized that disrupting the MAdCAM-1–α4β7 interaction might cause Treg17 cells to migrate from the gut to the tumors, thereby compromising the anticancer effects of immune checkpoint inhibitors (ICIs).[24] Accompanying this, she saw that the relocation of enterotropic and immunosuppressive Treg17 cells to cancerous tissue (tumors and tdLNs) is repressed by the molecular interaction between the HEV addressin MAdCAM-1 and the integrin α4β7 expressed by Treg17 cells.[24] Zitvogel's research also revealed that antibiotics administered before or during treatment may worsen the efficacy of immunotherapy.[25] She examined the connections between nutrition, inflammation, and the immune system's impact on cancer.[26] Correspondingly, Zitvogel found that nutritional interventions are emerging as novel strategies for improving the outcome of treatments with PD-1/PD-L1–targeting ICIs.[27] Continuing on with Zitvogel's cancer research, she found that probiotics used as a complement to the existing therapeutic arsenal (surgery, radiotherapy, chemotherapy, hormone therapy, immunotherapy) could become a sixth therapeutic modality against cancer.[28] Zitovgel's ongoing research falls into three main categories: studying the modes of action of immune checkpoint inhibitors, seeking predictors of response to immunomodulators, and defining the role of the gut microbiome in cancer immunosurveillance.[15]

Awards

[edit]

Zitvogel's awards include:

References

[edit]
  1. ^ a b c d "Laurence Zitvogel: Gut bacteria that cure cancer". Université Paris-Saclay. 11 February 2020. Retrieved 31 May 2024.
  2. ^ Jalinière, Hugo (20 March 2016). "Laurence Zitvogel: l'ennemie intime du cancer". Sciences et Avenir (in French). Retrieved 31 May 2024.
  3. ^ Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S. (May 1998). "Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes". Nature Medicine. 4 (5): 594–600. doi:10.1038/nm0598-594. ISSN 1078-8956. PMID 9585234.
  4. ^ a b Zitvogel, Laurence; Tesniere, Antoine; Kroemer, Guido (October 2006). "Cancer despite immunosurveillance: immunoselection and immunosubversion". Nature Reviews. Immunology. 6 (10): 715–727. doi:10.1038/nri1936. ISSN 1474-1733. PMID 16977338.
  5. ^ Vétizou, Marie; Daillère, Romain; Zitvogel, Laurence (November 2016). "[The role of intestinal microbiota in the response to anti-tumor therapies]". Médecine/Sciences. 32 (11): 974–982. doi:10.1051/medsci/20163211013. ISSN 1958-5381. PMID 28008838.
  6. ^ a b Fridman, Wolf H.; Teillaud, Jean-Luc; Sautès-Fridman, Catherine; Pagès, Franck; Galon, Jérôme; Zucman-Rossi, Jessica; Tartour, Eric; Zitvogel, Laurence; Kroemer, Guido (1 December 2011). "The Ultimate Goal of Curative Anti-Cancer Therapies: Inducing an Adaptive Anti-Tumor Immune Response". Frontiers in Immunology. 2: 66. doi:10.3389/fimmu.2011.00066. ISSN 1664-3224. PMC 3341952. PMID 22566855.
  7. ^ a b Goubet, Anne-Gaëlle; Wheeler, Richard; Fluckiger, Aurélie; Qu, Bo; Lemaître, Fabien; Iribarren, Kristina; Mondragón, Laura; Tidjani Alou, Maryam; Pizzato, Eugénie; Durand, Sylvère; Derosa, Lisa; Aprahamian, Fanny; Bossut, Noélie; Moya-Nilges, Maryse; Derrien, Diane (July 2021). "Multifaceted modes of action of the anticancer probiotic Enterococcus hirae". Cell Death and Differentiation. 28 (7): 2276–2295. doi:10.1038/s41418-021-00753-8. ISSN 1350-9047. PMC 8257780. PMID 33976389.
  8. ^ Jalinière, Hugo (20 March 2016). "Laurence Zitvogel: l'ennemie intime du cancer" [Laurence Zitvogel. The intimate enemy of cancer]. Science et Avenir (in French). Retrieved 26 June 2020.
  9. ^ Kroemer, Guido (2017). "Cancer cell stress and death – cell-autonomous and immunological considerations" (PDF). Charles Rodolphe Brupbacher Foundation. Retrieved 26 June 2020.
  10. ^ Barret, Anna-Laure (21 June 2017). "L'amour contre le cancer" [Love against cancer]. Le Journal de Dimanche (in French). Retrieved 26 June 2020.
  11. ^ "Laurence Zitvogel, MD, PhD - Gustave Roussy Cancer Centre: Antibody Engineering & Therapeutics Series Speaker". Informa Connect. Retrieved 31 May 2024.
  12. ^ Moreira, Sarah. "Laurence Zitvogel". The Barcelona Debates on the Human Microbiome 2024. Retrieved 31 May 2024.
  13. ^ "Zitvogel Laurence". www.ae-info.org. The Academy of Europe. Retrieved 23 June 2020.
  14. ^ "Shop Talk". Oncology Times. 39 (22): 69–71. 25 November 2017. doi:10.1097/01.COT.0000527395.64210.f0. ISSN 0276-2234.
  15. ^ a b c d ESMO. "First ESMO Award in Immuno-Oncology Goes to Laurence Zitvogel". www.esmo.org. Retrieved 31 May 2024.
  16. ^ "First ESMO Award for Immuno-Oncology Presented to Laurence Zitvogel, MD, PhD". The ASCO Post. 10 November 2017. Retrieved 31 May 2024.
  17. ^ "EverImmune appoints Prof. Laurence Zitvogel as president of scientific advisory board". Andrew Lloyd & Associates. Retrieved 31 May 2024.
  18. ^ Owens, Brian (1 February 2018). "Gut bacteria link to immunotherapy sparks interest". Nature Biotechnology. 36 (2): 121–122. doi:10.1038/nbt0218-121. ISSN 1546-1696. PMID 29406499.
  19. ^ Yonekura, Satoru (11 January 2017). theses.fr. thesses.fr (Thesis).
  20. ^ Zitvogel, Laurence (11 February 2020). "Des bacteries intestinales qui soignent les cancer". Universite de Paris-Sarclay.
  21. ^ "Laurence Zitvogel: Des bactéries intestinales qui soignent les cancers". Université Paris-Saclay (in French). 11 February 2020. Retrieved 23 June 2020.
  22. ^ Zitvogel, Laurence; Kroemer, Guido (1 November 2012). "Targeting PD-1/PD-L1 interactions for cancer immunotherapy". Oncoimmunology. 1 (8): 1223–1225. doi:10.4161/onci.21335. ISSN 2162-4011. PMC 3518493. PMID 23243584.
  23. ^ a b Fridman, Wolf H.; Teillaud, Jean-Luc; Sautès-Fridman, Catherine; Pagès, Franck; Galon, Jérôme; Zucman-Rossi, Jessica; Tartour, Eric; Zitvogel, Laurence; Kroemer, Guido (1 December 2011). "The Ultimate Goal of Curative Anti-Cancer Therapies: Inducing an Adaptive Anti-Tumor Immune Response". Frontiers in Immunology. 2: 66. doi:10.3389/fimmu.2011.00066. ISSN 1664-3224. PMC 3341952. PMID 22566855.
  24. ^ a b Fidelle, Marine; Rauber, Conrad; Alves Costa Silva, Carolina; Tian, Ai-Ling; Lahmar, Imran; de La Varende, Anne-Laure Mallard; Zhao, Liwei; Thelemaque, Cassandra; Lebhar, Isabelle; Messaoudene, Meriem; Pizzato, Eugenie; Birebent, Roxanne; Mbogning Fonkou, Maxime Descartes; Zoppi, Silvia; Reni, Anna (9 June 2023). "A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers". Science. 380 (6649). doi:10.1126/science.abo2296. ISSN 0036-8075.
  25. ^ a b "Bob Pinedo Cancer Care Award 2022 for Laurence Zitvogel - KNAW". knaw.nl (in Dutch). Retrieved 9 May 2024.
  26. ^ Zitvogel, Laurence; Pietrocola, Federico; Kroemer, Guido (August 2017). "Nutrition, inflammation and cancer". Nature Immunology. 18 (8): 843–850. doi:10.1038/ni.3754. ISSN 1529-2916. PMID 28722707.
  27. ^ Zitvogel, Laurence; Kroemer, Guido (1 June 2022). "Boosting the immunotherapy response by nutritional interventions". The Journal of Clinical Investigation. 132 (11). doi:10.1172/JCI161483. ISSN 0021-9738. PMC 9151683. PMID 35642631.
  28. ^ "Expert interview: Pr. Laurence Zitvogel". Biocodex Microbiota Institute. Retrieved 31 May 2024.
  29. ^ "Laurence Zitvogel, Prix Recherche Clinique et thérapeutique 2007" [Laurence Zitvogel, 2007 Clinical and Therapeutic Research Prize]. INSERM. Retrieved 26 June 2020.
  30. ^ a b "Academy of Europe: Zitvogel Laurence". www.ae-info.org. Retrieved 31 May 2024.
  31. ^ "Brupbacher Prize – Charles Rodolphe Brupbacher Foundation". Charles Rodolphe Brupbacher Stiftung. Retrieved 31 May 2024.
  32. ^ "Jakob-Herz Prize 2018". Faculty of Medicine. 5 February 2018. Retrieved 31 May 2024.
  33. ^ "Steve Jackson to receive ARC Foundation Léopold Griffuel Award". CRUK Cambridge Centre. Retrieved 31 May 2024.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Laurence_Zitvogel&oldid=1238231136"